1. Home
  2. SLVM vs HROW Comparison

SLVM vs HROW Comparison

Compare SLVM & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

HOLD

Current Price

$42.15

Market Cap

1.7B

ML Signal

HOLD

Logo Harrow Inc.

HROW

Harrow Inc.

HOLD

Current Price

$35.86

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLVM
HROW
Founded
1898
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SLVM
HROW
Price
$42.15
$35.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$54.00
$69.86
AVG Volume (30 Days)
341.3K
558.3K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
4.31%
N/A
EPS Growth
N/A
N/A
EPS
3.24
N/A
Revenue
$3,351,000,000.00
N/A
Revenue This Year
$0.98
$31.79
Revenue Next Year
$2.28
$49.04
P/E Ratio
$12.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.09
$21.18
52 Week High
$62.02
$54.98

Technical Indicators

Market Signals
Indicator
SLVM
HROW
Relative Strength Index (RSI) 48.76 44.29
Support Level $41.56 $32.79
Resistance Level $43.81 $37.41
Average True Range (ATR) 1.29 1.61
MACD 0.44 0.67
Stochastic Oscillator 84.71 57.31

Price Performance

Historical Comparison
SLVM
HROW

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.

Share on Social Networks: